79404 Federal Register / Vol. 75, No. 243 / Monday, December 20, 2010 / Notices 

VIII. Notification 

Unless such transaction is otherwise 

subject to the reporting and waiting period 

requirements of the Hart-Scott-Rodino 

Antitrust Improvements Act of 1976, as 

amended, 15 U.S.C. 18a (the ‘‘HSR Act’’), 

during the term of this Final Judgment, 

Defendants, without providing advance 

notification to the Antitrust Division, shall 

not directly or indirectly: (a) Acquire any 

assets of or any interest (including, but not 

limited to, any financial, security, loan, 

equity, or management interest) in, any 

company in the business of designing, 

developing, producing, marketing, servicing, 

distributing, and/or selling bonded insulated 

rail joints and/or polyurethane-coated 

insulated rail joints, or any company in the 

business of producing, marketing, 

distributing, and/or selling Friction 

Management Products; or (b) enter into any 

relationship with another company that 

involves the distribution of Friction 

Management Products in North America. 

Such notification shall be provided to the 

Antitrust Division in the same format as, and 

per the instructions relating to the 

Notification and Report Form set forth in the 

Appendix to Part 803 of Title 16 of the Code 

of Federal Regulations as amended, except 

that the information requested in Items 5 

through 9 of the instructions must be 

provided only about bonded insulated rail 

joints, polyurethane-coated insulated rail 

joints, and Friction Management Products. 

Notification shall be provided at least thirty 

(30) calendar days prior to acquiring any 

such interest, and shall include, beyond what 

may be required by the applicable 

instructions, the names of the principal 

representatives of the parties to the 

agreement who negotiated the agreement, 

and any management or strategic plans 

discussing the proposed transaction. If 

within the 30-day period after notification, 

representatives of the Antitrust Division 

make a written request for additional 

information, Defendants shall not 

consummate the proposed transaction or 

agreement until thirty (30) calendar days 

after submitting all such additional 

information. Early termination of the waiting 

periods in this paragraph may be requested 

and, where appropriate, granted in the same 

manner as is applicable under the 

requirements and provisions of the HSR Act 

and rules promulgated thereunder. This 

Section shall be broadly construed and any 

ambiguity or uncertainty regarding the filing 

of notice under this Section shall be resolved 

in favor of filing notice. 

IX. No Reacquisition 

Defendants may not reacquire any part of 

the Divestiture Assets during the term of this 

Final Judgment. 

X. Retention of Jurisdiction 

This Court retains jurisdiction to enable 

any party to this Final Judgment to apply to 

this Court at any time for further orders and 

directions as may be necessary or appropriate 

to carry out or construe this Final Judgment, 

to modify any of its provisions, to enforce 

compliance, and to punish violations of its 

provisions. 

XI. Expiration of Final Judgment 

Unless this Court grants an extension, this 

Final Judgment shall expire ten (10) years 

from the date of its entry. 

XII. Public Interest Determination 

Entry of this Final Judgment is in the 

public interest. The parties have complied 

with the requirements of the Antitrust 

Procedures and Penalties Act, 15 U.S.C. 16, 

including making copies available to the 

public of this Final Judgment, the 

Competitive Impact Statement, and any 

comments thereon and the United States’s 

responses to comments. Based upon the 

record before the Court, which includes the 

Competitive Impact Statement and any 

comments and responses to comments filed 

with the Court, entry of this Final Judgment 

is in the public interest. 

Court approval subject to procedures of 

Antitrust Procedures and Penalties Act, 15 

U.S.C. § 16 United States District Judge. 

[FR Doc. 2010–31863 Filed 12–17–10; 8:45 am] 

BILLING CODE 4410–11–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[DEA #343E] 

Controlled Substances: Established 

Initial Aggregate Production Quotas 

for 2011 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of aggregate production 

quotas for 2011. 

SUMMARY: This notice establishes initial 

2011 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). 

DATES: Effective Date: December 20, 

2010. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, PhD, Chief, Drug 

& Chemical Evaluation Section, Drug 

Enforcement Administration, 

Springfield, Virginia 22152, Telephone: 

(202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

The 2011 aggregate production quotas 

represent those quantities of controlled 

substances that may be produced in the 

United States in 2011 to provide 

adequate supplies of each substance for: 

the estimated medical, scientific, 

research, and industrial needs of the 

United States; lawful export 

requirements; and the establishment 

and maintenance of reserve stocks (21 

U.S.C. 826(a) and 21 CFR 1303.11). 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

On September 15, 2010, a notice of 

the proposed initial 2011 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register (75 

FR 56137). All interested persons were 

invited to comment on or object to these 

proposed aggregate production quotas 

on or before October 15, 2010. 

Seven responses (six from DEA 

registered manufacturers, and one from 

a non-DEA registrant) were received 

within the published comment period, 

offering comments on a total of 31 

schedules I and II controlled substances. 

The commenters stated that the 

proposed aggregate production quotas 

for 3,4-methylenedioxyamphetamine, 

3,4-methylenedioxy-Nethylamphetamine, 3,4- 

methylenedioxymethamphetamine, 

4-anilino-N-phenethyl-4-piperidine, 

amphetamine (for sale), cathinone, 

codeine (for sale), dihydromorphine, 

fentanyl, gamma hydroxybutyric acid, 

heroin, hydrocodone, hydromorphone, 

marihuana, meperidine, methaqualone, 

methylphenidate, morphine (for 

conversion), morphine (for sale), 

nabilone, noroxymorphone (for 

conversion), opium (tincture), 

oxycodone (for sale), pentobarbital, 

phencyclidine, remifentanil, 

secobarbital, tapentadol, 

tetrahydrocannabinols, thebaine and 

tilidine were insufficient to provide for 

the estimated medical, scientific, 

research, and industrial needs of the 

United States, for export requirements 

and for the establishment and 

maintenance of reserve stocks. 

In arriving at the aggregate production 

quotas, DEA has taken into 

consideration the above comments 

along with the factors set forth at 21 

CFR 1303.11(b) and other relevant 2010 

factors, including 2010 manufacturing 

quotas, current 2010 sales and 

inventories, 2011 export requirements, 

additional applications received, as well 

as research and product development 

requirements. Based on this 

information, DEA has adjusted the 

initial aggregate production quotas for 

3,4-methylenedioxyamphetamine, 3,4- 

methylenedioxy-N-ethylamphetamine, 

3,4-methylenedioxymethamphetamine, 

amobarbital, cathinone, 

dimethyltryptamine, ibogaine, lysergic 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 243 / Monday, December 20, 2010 / Notices 79405 

acid diethylamide, metazocine, 

methaqualone, nabilone, normorphine, 

noroxymorphone (for sale), 

phenazocine, phencyclidine, 

secobarbital, and tetrahydrocannabinols 

to meet the legitimate needs of the 

United States. 

Regarding 4-anilino-N-phenethyl-4- 

piperidine, amphetamine (for sale), 

codeine (for sale), dihydromorphine, 

fentanyl, gamma hydroxybutyric acid, 

heroin, hydrocodone, hydromorphone, 

marihuana, meperidine, 

methylphenidate, morphine (for 

conversion), morphine (for sale), 

noroxymorphone (for conversion), 

opium (tincture), oxycodone (for sale), 

pentobarbital, remifentanil, tapentadol, 

thebaine and tilidine DEA has 

determined that the proposed initial 

2011 aggregate production quotas are 

sufficient to meet the current 2011 

estimated medical, scientific, research, 

and industrial needs of the United 

States. 

Pursuant to 21 CFR 1303, the Deputy 

Administrator of DEA will, in 2011, 

adjust aggregate production quotas and 

individual manufacturing quotas 

allocated for the year based upon 2010 

year-end inventory and actual 2010 

disposition data supplied by quota 

recipients for each basic class of 

schedule I or II controlled substance. 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA (21 U.S.C. 826), and 

delegated to the Administrator of DEA 

by 28 CFR 0.100, and redelegated to the 

Deputy Administrator pursuant to 28 

CFR 0.104, the Deputy Administrator 

hereby orders that the 2011 initial 

aggregate production quotas for the 

following controlled substances, 

expressed in grams of anhydrous acid or 

base, be established as follows: 

Basic class—Schedule I Established 2011 

quotas 

1-Methyl-4-phenyl-4-propionoxypiperidine ............................................................................................................................... 2 g 

2,5-Dimethoxyamphetamine .................................................................................................................................................... 2 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) .......................................................................................................................... 2 g 

2,5-Dimethoxy-4-n-propylthiophenethylamine ......................................................................................................................... 2 g 

3-Methylfentanyl ....................................................................................................................................................................... 2 g 

3-Methylthiofentanyl ................................................................................................................................................................. 2 g 

3,4-Methylenedioxyamphetamine (MDA) ................................................................................................................................ 22 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................................................. 15 g 

3,4-Methylenedioxymethamphetamine (MDMA) ..................................................................................................................... 22 g 

3,4,5-Trimethoxyamphetamine ................................................................................................................................................ 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) .......................................................................................................................... 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ...................................................................................................................... 2 g 

4-Methoxyamphetamine .......................................................................................................................................................... 77 g 

4-Methylaminorex .................................................................................................................................................................... 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) .......................................................................................................................... 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine .......................................................................................................................... 2 g 

5-Methoxy-N,N-diisopropyltryptamine ...................................................................................................................................... 2 g 

Acetyl-alpha-methylfentanyl ..................................................................................................................................................... 2 g 

Acetyldihydrocodeine ............................................................................................................................................................... 2 g 

Acetylmethadol ........................................................................................................................................................................ 2 g 

Allylprodine .............................................................................................................................................................................. 2 g 

Alphacetylmethadol .................................................................................................................................................................. 2 g 

Alpha-ethyltryptamine .............................................................................................................................................................. 2 g 

Alphameprodine ....................................................................................................................................................................... 2 g 

Alphamethadol ......................................................................................................................................................................... 2 g 

Alpha-methylfentanyl ............................................................................................................................................................... 2 g 

Alpha-methylthiofentanyl .......................................................................................................................................................... 2 g 

Alpha-methyltryptamine (AMT) ................................................................................................................................................ 2 g 

Aminorex .................................................................................................................................................................................. 2 g 

Benzylmorphine ....................................................................................................................................................................... 2 g 

Betacetylmethadol ................................................................................................................................................................... 2 g 

Beta-hydroxy-3-methylfentanyl ................................................................................................................................................ 2 g 

Beta-hydroxyfentanyl ............................................................................................................................................................... 2 g 

Betameprodine ......................................................................................................................................................................... 2 g 

Betamethadol ........................................................................................................................................................................... 2 g 

Betaprodine .............................................................................................................................................................................. 2 g 

Bufotenine ................................................................................................................................................................................ 3 g 

Cathinone ................................................................................................................................................................................. 4 g 

Codeine-N-oxide ...................................................................................................................................................................... 602 g 

Diethyltryptamine ..................................................................................................................................................................... 2 g 

Difenoxin .................................................................................................................................................................................. 3,000 g 

Dihydromorphine ...................................................................................................................................................................... 3,608,000 g 

Dimethyltryptamine .................................................................................................................................................................. 7 g 

Gamma-hydroxybutyric acid .................................................................................................................................................... 3,000,000 g 

Heroin ...................................................................................................................................................................................... 20 g 

Hydromorphinol ........................................................................................................................................................................ 2 g 

Hydroxypethidine ..................................................................................................................................................................... 2 g 

Ibogaine ................................................................................................................................................................................... 5 g 

Lysergic acid diethylamide (LSD) ............................................................................................................................................ 16 g 

Marihuana ................................................................................................................................................................................ 21,000 g 

Mescaline ................................................................................................................................................................................. 5 g 

Methaqualone .......................................................................................................................................................................... 10 g 

Methcathinone ......................................................................................................................................................................... 4 g 

Methyldihydromorphine ............................................................................................................................................................ 2 g 

Morphine-N-oxide .................................................................................................................................................................... 605 g 


jlentini on DSKJ8SOYB1PROD with NOTICES
79406 Federal Register / Vol. 75, No. 243 / Monday, December 20, 2010 / Notices 

Basic class—Schedule I Established 2011 

quotas 

N-Benzylpiperazine .................................................................................................................................................................. 2 g 

N,N-Dimethylamphetamine ...................................................................................................................................................... 2 g 

N-Ethylamphetamine ............................................................................................................................................................... 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine .......................................................................................................................... 2 g 

Noracymethadol ....................................................................................................................................................................... 2 g 

Norlevorphanol ......................................................................................................................................................................... 52 g 

Normethadone ......................................................................................................................................................................... 2 g 

Normorphine ............................................................................................................................................................................ 18 g 

Para-fluorofentanyl ................................................................................................................................................................... 2 g 

Phenomorphan ........................................................................................................................................................................ 2 g 

Pholcodine ............................................................................................................................................................................... 2 g 

Psilocybin ................................................................................................................................................................................. 2 g 

Psilocyn .................................................................................................................................................................................... 2 g 

Tetrahydrocannabinols ............................................................................................................................................................ 393,000 g 

Thiofentanyl ............................................................................................................................................................................. 2 g 

Tilidine ...................................................................................................................................................................................... 10 g 

Trimeperidine ........................................................................................................................................................................... 2 g 

Basic class—Schedule II Established 2011 

quotas 

1-Phenylcyclohexylamine ........................................................................................................................................................ 2 g 

1-piperdinocyclohexanecarbonitrile ......................................................................................................................................... 2 g 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................................. 2,500,000 g 

Alfentanil .................................................................................................................................................................................. 8,000 g 

Alphaprodine ............................................................................................................................................................................ 2 g 

Amobarbital .............................................................................................................................................................................. 40,007 g 

Amphetamine (for conversion) ................................................................................................................................................ 7,500,000 g 

Amphetamine (for sale) ........................................................................................................................................................... 18,600,000 g 

Cocaine .................................................................................................................................................................................... 247,000 g 

Codeine (for conversion) ......................................................................................................................................................... 65,000,000 g 

Codeine (for sale) .................................................................................................................................................................... 39,605,000 g 

Dextropropoxyphene ................................................................................................................................................................ 92,000,000 g 

Dihydrocodeine ........................................................................................................................................................................ 800,000 g 

Diphenoxylate .......................................................................................................................................................................... 827,000 g 

Ecgonine .................................................................................................................................................................................. 83,000 g 

Ethylmorphine .......................................................................................................................................................................... 2 g 

Fentanyl ................................................................................................................................................................................... 1,428,000 g 

Glutethimide ............................................................................................................................................................................. 2 g 

Hydrocodone (for sale) ............................................................................................................................................................ 55,000,000 g 

Hydromorphone ....................................................................................................................................................................... 3,455,000 g 

Isomethadone .......................................................................................................................................................................... 11 g 

Levo-alphacetylmethadol (LAAM) ............................................................................................................................................ 3 g 

Levomethorphan ...................................................................................................................................................................... 5 g 

Levorphanol ............................................................................................................................................................................. 10,000 g 

Lisdexamfetamine .................................................................................................................................................................... 9,000,000 g 

Meperidine ............................................................................................................................................................................... 6,600,000 g 

Meperidine Intermediate-A ...................................................................................................................................................... 3 g 

Meperidine Intermediate-B ...................................................................................................................................................... 7 g 

Meperidine Intermediate-C ...................................................................................................................................................... 3 g 

Metazocine ............................................................................................................................................................................... 5 g 

Methadone (for sale) ............................................................................................................................................................... 20,000,000 g 

Methadone Intermediate .......................................................................................................................................................... 26,000,000 g 

Methamphetamine ................................................................................................................................................................... 3,130,000 g 

[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] 

Methylphenidate ....................................................................................................................................................................... 50,000,000 g 

Morphine (for conversion) ........................................................................................................................................................ 83,000,000 g 

Morphine (for sale) .................................................................................................................................................................. 39,000,000 g 

Nabilone ................................................................................................................................................................................... 10,502 g 

Noroxymorphone (for conversion) ........................................................................................................................................... 9,000,000 g 

Noroxymorphone (for sale) ...................................................................................................................................................... 401,000 g 

Opium (powder) ....................................................................................................................................................................... 230,000 g 

Opium (tincture) ....................................................................................................................................................................... 1,500,000 g 

Oripavine .................................................................................................................................................................................. 15,000,000 g 

Oxycodone (for conversion) .................................................................................................................................................... 5,600,000 g 

Oxycodone (for sale) ............................................................................................................................................................... 105,500,000 g 

Oxymorphone (for conversion) ................................................................................................................................................ 12,800,000 g 

Oxymorphone (for sale) ........................................................................................................................................................... 3,070,000 g 

Pentobarbital ............................................................................................................................................................................ 28,000,000 g 

Phenazocine ............................................................................................................................................................................ 5 g 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 243 / Monday, December 20, 2010 / Notices 79407 

Basic class—Schedule II Established 2011 

quotas 

Phencyclidine ........................................................................................................................................................................... 24 g 

Phenmetrazine ......................................................................................................................................................................... 2 g 

Phenylacetone ......................................................................................................................................................................... 8,000,000 g 

Racemethorphan ..................................................................................................................................................................... 2 g 

Remifentanil ............................................................................................................................................................................. 2,500 g 

Secobarbital ............................................................................................................................................................................. 260,002 g 

Sufentanil ................................................................................................................................................................................. 7,000 g 

Tapentadol ............................................................................................................................................................................... 1,000,000 g 

Thebaine .................................................................................................................................................................................. 126,000,000 g 

The Deputy Administrator further 

orders that aggregate production quotas 

for all other schedules I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 be established 

at zero. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of State law; nor 

does it impose enforcement 

responsibilities on any State; nor does it 

diminish the power of any State to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research, and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by State, local, and Tribal 

governments, in the aggregate, or by the 

private sector, of $126,400,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: December 10, 2010. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. 2010–31849 Filed 12–17–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–350E] 

Established Assessment of Annual 

Needs for the List I Chemicals 

Ephedrine, Pseudoephedrine, and 

Phenylpropanolamine for 2011 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of Assessment of Annual 

Needs for 2011. 

SUMMARY: This notice establishes the 

initial 2011 Assessment of Annual 

Needs for certain List I chemicals in 

accordance with the Combat 

Methamphetamine Epidemic Act of 

2005 (CMEA). 

DATES: Effective Date: December 20, 

2010. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, PhD, Chief, Drug 

and Chemical Evaluation Section, Drug 

Enforcement Administration, 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

713 of the Combat Methamphetamine 

Epidemic Act of 2005 (Title VII of 

Pub. L. 109–177) (CMEA) amended 

Section 306 of the Controlled 

Substances Act (CSA) (21 U.S.C. 826) by 

adding ephedrine, pseudoephedrine, 

and phenylpropanolamine to existing 

language to read as follows: ‘‘The 

Attorney General shall determine the 

total quantity and establish production 

quotas for each basic class of controlled 

substance in schedules I and II and for 

ephedrine, pseudoephedrine, and 

phenylpropanolamine to be 

manufactured each calendar year to 

provide for the estimated medical, 

scientific, research, and industrial needs 

of the United States, for lawful export 

requirements, and for the establishment 

and maintenance of reserve stocks.’’ 

Further, section 715 of the CMEA 

amended 21 U.S.C. 952 ‘‘Importation of 

Controlled Substances’’ by adding the 

same List I chemicals to the existing 

language in paragraph (a), and by 

adding a new paragraph (d) to read as 

follows: 

(a) Controlled substances in schedule I or 

II and narcotic drugs in schedule III, IV, or 

V; exceptions 

It shall be unlawful to import into the 

customs territory of the United States from 

any place outside thereof (but within the 

United States), or to import into the United 

States from any place outside thereof, any 

controlled substance in schedule I or II of 

subchapter I of this chapter, or any narcotic 

drug in schedule III, IV, or V of subchapter 

I of this chapter, or ephedrine, 

pseudoephedrine, and 

phenylpropanolamine, except that— 

(1) such amounts of crude opium, poppy 

straw, concentrate of poppy straw, and coca 

leaves, and of ephedrine, pseudoephedrine, 

and phenylpropanolamine, as the Attorney 

General finds to be necessary to provide for 

medical, scientific, or other legitimate 

purposes * * * may be so imported under 

such regulations as the Attorney General 

shall prescribe. 

* * * * * 

(d)(1) With respect to a registrant under 

section 958 who is authorized under 

subsection (a)(1) to import ephedrine, 

pseudoephedrine, or phenylpropanolamine, 

at any time during the year the registrant may 

apply for an increase in the amount of such 

chemical that the registrant is authorized to 

import, and the Attorney General may 


jlentini on DSKJ8SOYB1PROD with NOTICES